MIT’s David H. Koch Institute of Integrative Cancer Research is partnering with Ortho-McNeil-Janssen Pharmaceuticals Inc. over cancer research and technology.
Called the Transcend program, the strategic partnership involves a 5-year renewable research effort in which Koch Institute faculty, staff and students will support the study of tumor microenvironments. MIT faculty and New Jersey-based Ortho-McNeil Janssen employees will form a joint scientific steering committee to direct the Transcend program. The program is expected to cover such research areas as cancer diagnostics, cancer biology pre-malignancies and genetic disease models.
Founded in 2007, the Koch Institute houses 25 MIT faculty members, with cancer research covering areas like nanotherapeutics, metastasis, cancer immunology, mapping of drug sensitivity and resistance pathways, and detection and monitoring.
The institute was designated a Center for Cancer Systems Biology in March by the National Cancer Institute.